Business Information
The group's principal activity is to apply value-added technologies to the process of bringing new drug therapies and healthcare products to global markets. The group operates in two segments: pharmaceutical systems segment, which designs, manufactures and sells stoppers, closures, medical device components and provides contract laboratory services for testing injectable drug packaging. The drug delivery systems segment identifies and develops drug delivery systems for biopharmaceutical and other drugs to improve their therapeutic performance and/or their method of administration. The drug delivery system also provides clinical research for phase I, II and III studies and clinical and marketing research services mostly for consumer products organizations.
|
|
Name |
Title
|
Email
|
| Donald Morel | Chmn., CEO, Pres. | N/A | | Donald McMillan | Pres. - North America Pharmaceutical Systems Division | N/A | | Robert Hargesheimer | Pres. - Tech Group | N/A | | Robert Keating | Pres. - Europe, Asia Pacific, Pharmaceutical Systems Division | N/A | | Steven Ellers | COO, Pres. | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 913,300 | 67,100 | | 2005 | 699,700 | 45,600 | | 2004 | 541,600 | 19,400
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
